Tetrahydrothieno pyridine derivatives as DDRs inhibitors

A compound of formula (I)

• wherein
• Rx, Ry and Rz are independently H or —(C1-C4)alkyl;
• L is selected from the group consisting of —C(O)— and —CH2—;
• Hy is a bicyclic heteroaryl optionally substituted with at least one substituent selected from the group consisting of —(C1-C4)alkyl, a halogen atom, cyano, —O—(C1-C4)alkyl,
• —O—(C1-C4)alkylene-OH, —O—(C1-C4)alkylene-O—(C1-C4)alkyl, —O—(C1-C4)alkylene-heterocycloalkyl, —(C1-C4)alkylene-NR4R5, —(C1-C6)haloalkyl and heterocycloalkyl optionally substituted by one or more —(C1-C4)alkyl, or Hy is a bicyclic semisaturated heteroaryl;
• R1 is selected from the group consisting of Het and X:
• Het is a heteroaryl optionally substituted with one or more substituents selected from the group consisting of —(C1-C4)alkyl, —(C1-C4)haloalkyl, cycloalkyl optionally substituted by one or more —(C1-C6)haloalkyl, —O—(C1-C4)haloalkyl, —O—(C1-C4)alkyl,
• —(C1-C4)alkylene-OH, —(C1-C4)alkylene-NR4R5, heterocycloalkyl, —(C1-C4)alkylene-aryl and aryl, wherein said aryl is optionally substituted with one or more groups selected from
• —(C1-C4)alkyl and a halogen atom, and
• X
• wherein
• R2 is H or is selected from the group consisting of —O(C1-C4)haloalkyl, a halogen atom, —O-cycloalkyl and —(C1-C4)haloalkyl;
• R3 is H or is selected from the group consisting of a halogen atom, cyano, heterocycloalkyl optionally substituted by one or more —(C1-C4)alkyl,
• —(C1-C4)alkylene-heterocycloalkyl, —(C1-C4)alkylene-heterocycloalkyl-(CH2)n—NR4R5,
• —(C1-C4)alkylene-NR4R5, —(C1-C4)alkylene-NR4R6, —O(C1-C4)alkyl, —O(C1-C4)haloalkyl,
• —O—(C1-C4)alkylene-OH, heteroaryl optionally substituted with —(C1-C4)alkyl,
• —O—(C1-C4)alkylene-NR4R5, —O—(C1-C4)alkylene-O—(C1-C4)alkyl,
• —O—(C1-C4)alkylene-heterocycloalkyl and —O-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted with one or more groups selected from
• —(C1-C4)alkyl, oxo, a halogen atom, —C(O)—(C1-C4)alkyl and heterocycloalkyl;
• n is 0, 1 or 2;
• R4 is H or —(C1-C4)alkyl;
• R5 is H or —(C1-C4)alkyl;
• R6 is selected from the group consisting of -heterocycloalkyl,
• —(C1-C4)alkylene-O—(C1-C4)alkyl and —(C1-C4)alkylene-OH;
• or a pharmaceutically acceptable salt thereof.